ADA Scientific Sessions 2026 Abstract

Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital

By Amanda R. Purcell, Matilda S. G. Longfield, Sarah J. Glastras

Study in peopleInterventions

The paper

Amanda R. Purcell, Matilda S. G. Longfield, Sarah J. Glastras

Sydney

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1729-P

doi.org/10.2337/db26-1729-p

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity